摘要
近年来,鉴于Blinatumomab在治疗难治/复发性(relapsed/refractory,R/R)急性B淋巴细胞白血病(B cell-acute lympho-blastic leukemia,B-ALL)及微小残留病变(minimal residual disease,MRD)阳性 B-ALL中的良好效果,各国学者对其在B-ALL早期治疗中的作用开展了广泛研究,Blinatumomab作为儿童B-ALL患者巩固治疗或强化化疗的替代治疗有堪比标准化疗的疗效;其作为早期巩固治疗或联合化疗/靶向治疗,可显著改善成人B-ALL患者预后,尤其是Blinatumomab联用第 3代酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs),可减少费城染色体阳性(philadelphia chromosome-positive,Ph+)B-ALL患者对异基因造血干细胞移植(allogeneic hematopoietic stem cell transplantation,allo-HSCT)的依赖;对于老年患者,Blinatumomab较化疗更为温和、安全及有效;KMT2A重排婴儿B-ALL尚无有效疗法,现有研究初步证实,Blinatumomab有望在此类患者的治疗中取得突破进展.本文对Blinatumomab在新诊断B-ALL中的研究进展进行综述.
Abstract
In recent years,interest in exploring the potential of Blinatumomab for treatment of B-cell acute lymphoblastic leukemia(B-ALL)at earlier stages has grown.This is because Blinatumomab has shown promising results in the management of refractory/relapsed(R/R)B-ALL and minimal residual disease(MRD).Blinatumomab has shown comparable efficacy to that of conventional chemotherapy as an altern-ative to consolidation or intensive chemotherapy in pediatric B-ALL patients.Moreover,its use as consolidation therapy or in combination with chemotherapy/targeted therapy,especially in combination with third-generation tyrosine kinase inhibitors(TKIs),shows significant promise for improving prognosis for adult B-ALL patients.This may potentially reduce reliance on allogeneic hematopoietic stem cell trans-plantation(allo-HSCT)in Philadelphia chromosome-positive(Ph+)B-ALL patients.Moreover,Blinatumomab is safer,gentler,and more effect-ive than chemotherapy for older adult patients.Effective therapy options are not yet available for infants with KMT2A rearrangement B-ALL;however,preliminary research indicates that Blinatumomab may offer a breakthrough for this subgroup.In this article,we review progress in investigations of Blinatumomab use in newly diagnosed B-ALL patients.
基金项目
天津市科技计划(21JCZDJC01170)
中国医科院医学与健康科技创新工程项目(2021-I2M-C&T-B-080)
中国医科院医学与健康科技创新工程项目(2021-I2M-1-017)
细胞生态海河实验室创新基金(22HHXBSS00036)
南京市卫生科技发展专项(YKK21273)
NETL
NSTL
万方数据